ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Postoperative osteoporosis therapy and risk of re-fracture in elderly patients with hip fractures: a multicenter retrospective cohort study.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Associations Between Peripheral Blood Inflammatory and Immune Markers and Osteoporotic and Fragility Fractures: A Systematic Review and Meta-Analysis.Calcified tissue international · 2026Pooled it
- Secondary fragility fractures after hip fracture surgery in four thousand, four hundred and eighteen older adults: risk factors and internal validation of an interpretable machine-learning model.International orthopaedics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This multicenter retrospective cohort study investigated the impact of guideline-concordant osteoporosis therapy on refracture risk and the timing of contralateral hip fractures in elderly patients following hip fracture surgery. PURPOSE: To evaluate whether osteoporosis treatment reduces the risk of subsequent fractures and prolongs the interval between initial and contralateral hip fractures in older adults.
methodsPatients aged ≥ 65 years who underwent hip fracture surgery between January 2010 and December 2024 at three teaching hospitals were included. Patients were assigned to treatment or no treatment groups based on whether they received guideline-recommended osteoporosis therapy postoperatively. Propensity score matching (1:1) adjusted for baseline differences. Refracture risk was assessed using Kaplan-Meier analysis and Cox regression. A sub-cohort analysis examined the time to contralateral hip fracture in patients with bilateral fractures.
resultsAfter matching, 1986 patients were included in the primary analysis. The osteoporosis treatment group had a significantly lower refracture rate (22.6% vs. 39.3%, p < 0.001) and longer median refracture-free survival (42 vs. 26 months, p < 0.001). Osteoporosis therapy was associated with an 89% relative reduction in refracture risk (HR = 0.11, 95% CI: 0.07-0.18, p < 0.001). Among 192 patients with bilateral hip fractures, the time to contralateral fracture was significantly longer in the osteoporosis treatment group (40.5 vs. 27.0 months, p < 0.001).
conclusionPostoperative osteoporosis therapy significantly lowers refracture risk and delays contralateral hip fracture. Integrating such treatment into routine postoperative care is essential for effective secondary fracture prevention.
Indexed as
Identifiers
41320716What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.